latest news in companies
Regulators Reject Union Pacific and Norfolk Southern Merger Application Over Missing Data
Homewood, Saturday, 17 January 2026.
Federal regulators rejected the historic Union Pacific and Norfolk Southern merger bid, deeming the massive 7,000-page application incomplete and effectively pausing the first transcontinental railroad deal.
$174 Million Financing Package Unlocks Major Santa Maria Housing Development
Santa Maria, Friday, 16 January 2026.
Priority Capital Advisory has secured a strategic $174 million financing package for Blosser Ranch, directly addressing a severe supply-demand imbalance in Santa Maria where population growth has outnumbered new housing deliveries by nearly ten to one over the last decade. This capital injection funds the immediate construction of 302 apartment units and recapitalizes land for a future 1,500-unit master-planned community near Vandenberg Space Force Base. Backed by Centennial Bank and Lionheart Strategic Management, this deal signals strong institutional confidence in the region’s agricultural and aerospace-driven economy, with the first phase expected to open by summer 2027.
Ardent Health Facing Class Action Lawsuit After Stock Plunges 33%
New York, Friday, 16 January 2026.
Investors face a critical March 9 deadline to join a securities fraud lawsuit against Ardent Health. The complaint alleges the company concealed failing revenue collection processes behind misleading accounting practices, triggering a massive sell-off that erased a third of the stock’s value overnight.
Denny's Enters Private Ownership Era Following $620 Million Acquisition
Spartanburg, Friday, 16 January 2026.
Denny’s Corporation officially exited the public market today, January 16, 2026, finalizing a $620 million acquisition by a consortium led by TriArtisan Capital Advisors. In a strategic pivot designed to revitalize the iconic brand away from public scrutiny, shareholders received $6.25 per share—a notable 52.1% premium over the pre-announcement closing price. This transaction places the 1,500-unit chain under private control, empowering leadership to aggressively pursue growth initiatives and capital reallocation without the pressure of quarterly public reporting.
Genmab’s Epcoritamab Outperforms Standard Care in Pivotal Phase 3 Lymphoma Trial
Copenhagen, Friday, 16 January 2026.
Epcoritamab becomes the first bispecific antibody monotherapy to demonstrate improved progression-free survival in refractory large B-cell lymphoma, reducing progression risk by 26% versus standard chemotherapy.
Soleno Therapeutics Faces Investigation After Disappointing Drug Launch Metrics
Redwood City, Friday, 16 January 2026.
Soleno shares plummeted following allegations of misleading VYKAT XR launch metrics. Investigations now probe claims that data was manipulated by a controversial physician, raising serious concerns for investors.
